International Journal of Advanced and Integrated Medical Sciences

Register      Login

VOLUME 2 , ISSUE 4 ( 2017 ) > List of Articles

ORIGINAL ARTICLE

Cutaneous Manifestations in Internal Malignancy

Navtej Singh

Keywords : Cutaneous, Malignancy, Metastases

Citation Information : Singh N. Cutaneous Manifestations in Internal Malignancy. Int J Adv Integ Med Sci 2017; 2 (4):161-168.

DOI: 10.5005/jp-journals-10050-10097

License: CC BY-SA 4.0

Published Online: 01-06-2018

Copyright Statement:  Copyright © 2017; The Author(s).


Abstract

Introduction The skin is a mirror of the internal milieu of the body. As with other systemic disorders, many internal malignancies can be reflected in this mirror, provided we look carefully enough. Internal malignancies may lead to cutaneous manifestations in a number of ways. The tumor may invade the skin directly or do so by way of lymphatic or hematogenous dissemination, thereby giving rise to deposits in the skin (cutaneous metastases). As is evident from the foregoing, a knowledge of cutaneous manifestations in various internal malignancies can be extremely helpful in making a diagnosis, gauging the extent of the disease, assessing the progress and response to therapy of a neoplasm besides enabling one to prognosticate. Materials and methods The study comprised 225 cases with internal malignant disease of varying types and duration and involving different organs and organ systems, recorded over a period of 1 year and 8 months. A thorough history and examination with relevant laboratory investigations with skin biopsy were carried out where indicated. Results The patients studied comprised 130 males (58%) and 95 females (42%) with maximum number of patients in the age group of 61 years and above. Mucocutaneous manifestations were seen in 52 (23%) patients in the present study with a total of 73 skin lesions of various types. Specific skin lesions were seen in 11 patients, paraneoplastic skin syndromes/nonspecific skin lesions were seen in 27, genetic syndromes denoting increased susceptibility to cancer in 1 and skin lesions due to cancer therapy in 21 patients; 14 (8.6%) out of 163 patients given chemotherapy showed adverse effects of chemotherapy; 7 patients (7.1%) out of a total of 98 given radiotherapy showed features of radiodermatitis in the present work. How to cite this article Singh N. Cutaneous Manifestations in Internal Malignancy. Int J Adv Integ Med Sci 2017;2(4):161-168.


PDF Share
  1. Ellis DL, Kafka SP, Chow JC, Nanney LB, Inman WH, McCadden ME, King LE Jr. Melanoma, growth factors, acanthosis nigricans, the sign of Leser-Trelat, and multiple acrochordons: a possible role for alpha-transforming growth factor in cutaneous paraneoplastic syndromes. N Engl J Med 1987 Dec;317(25):1582-1587.
  2. Swift M, Morrell D, Massey RB, Chase CL. Incidence of cancer in 161 families affected by ataxia-telangiectasia. N Engl J Med 1991 Dec;325(26):1831-1836.
  3. Fischer, D.; Knobf, M.; Durivage, H. The cancer chemotherapy handbook. St. Louis (MO): Mosby; 1997. pp. 514-526.
  4. Susser WS, Whitaker-Worth DL, Grant-Kels JM. Mucocutaneous reactions to chemotherapy. J Am Acad Dermatol 1999 Mar;40(3):367-398.
  5. Goldschmidt H, Sherwin WK. Reactions to ionizing radiation. J Am Acad Dermatol 1980 Dec;3(6):551-579.
  6. Spencer PS, Helm TN. Skin metastases in cancer patients. Cutis 1987 Feb;39(2):119-121.
  7. Lookingbill DP, Spangler N, Helm KF. Cutaneous metastases in patients with metastatic carcinoma: a retrospective study of 4020 patients. J Am Acad Dermatol 1993 Aug;29(2 Pt 1):228-236.
  8. Brownstein MH, Helwig EB. Patterns of cutaneous metastasis. Arch Dermatol 1972 Jun;105(6):862-865.
  9. Bansal R, Naik R. A study of 70 cases of cutaneous metastases from internal carcinoma. J Indian Med Assoc 1998; 96:10-12.
  10. Lookingbill DP, Spangler N, Sexton FM. Skin involvement as the presenting sign of internal carcinoma: a retrospective study of 7316 cancer patients. J Am Acad Dermatol 1990 Jan;22(1):19-26.
  11. Tharakaram S. Metastases to the skin. Int J Dermatol 1988 May;27(4):240-242.
  12. Kato N, Yasukawa K, Kimura K, Yoshida K. Anaplastic large-cell lymphoma associated with acquired ichthyosis. J Am Acad Dermatol 2000 May;42(5 Pt 2):914-920.
  13. Rand RE, Baden HP. The ichthyosis: a review. J Am Acad Dermatol 1983 Mar;8(3):285-305.
  14. McLean, DI.; Haynes, HA. Cutaneous manifestations of internal malignant disease. In: Freedberg IM, Eisen AZ, Wolff K, Austen KF, Goldsmith LA, Katz SI, Fitzpatrick TB, editors. Fitzpatrick's dermatology in general medicine. 5th ed. New York: McGraw-Hill; 1999. pp. 2106-2120.
  15. O'Bryan-Tear CG, Burke M, Coulston IH, Marsden RA. Hodgkin's disease presenting in the skin. Clin Exp Dermatol 1987 Jan;12(1):69-71.
  16. Smith JB, Fenske NA. Herpes zoster and internal malignancy. South Med J 1995 Nov;88(11):1089-1092.
  17. Minna, JD. Neoplasms of the lung. In: Fauci AS, Braunwald E, Isselbacher KJ, Wilson JD, Martin JB, Kasper D, Hauser SL, Longo DL, editors. Harrison's principles of internal medicine. 14th ed. New York: McGraw-Hill; 1998. pp. 552-561.
  18. Kiszka-Kanowitz M, Nielsen NA. Hypertrophic pulmonary osteoarthropathy. A paraneoplastic syndrome associated with lung cancer. Ugeskr Laeger 2000 Jan;162(4):503-504.
  19. Freedman, AS.; Nadler, LM. Malignancies of lymphoid cells. In: Fauci AS, Braunwald E, Isselbacher KJ, Wilson JD, Martin JB, Kasper D, Hauser SL, Longo DL, editors. Harrison's principles of internal medicine. 14th ed. New York: McGraw-Hill; 1998. pp. 695-712.
  20. Lindelof B, Islam N, Eklund G, Arfors L. Pemphigoid and cancer. Arch Dermatol 1990 Jan;126(1):66-68.
  21. Dahl MV, Ristow S. Bullous pemphigoid and ovarian cystadenocarcinoma: immunologic studies. Arch Dermatol 1978 Jun;114(6):903-905.
  22. Daoud, MS.; Pittelkow, MR. Pityriasis lichenoides. In: Freedberg IM, Eisen AZ, Wolff K, Austen KF, Goldsmith LA, Katz SI, Fitzpatrick TB, editors. Fitzpatrick's dermatology in general medicine. 5th ed. New York: McGraw-Hill; 1999. pp. 553-560.
  23. Litt, JZ. Drug eruption reference manual. New York: Parthenon Publishing; 1998. p. 564.
  24. Tosi A, Misciali C, Piraccini B, Peluso AM, Bardazzi F. Drug-induced hair loss and hair growth. Incidence, management and avoidance. Drug Saf 1994 Apr;10(4):310-317.
  25. Bronner AK, Hood AF. Cutaneous complication of chemotherapeutic agents. J Am Acad Dermatol 1983 Nov;9(5):645-663.
  26. Hood AF. Cutaneous side effects of cancer chemotherapy. Med Clin North Am 1986 Jan;70(1):187-209.
  27. Boyle DM, Engelking C. Vesicant extravasation: myths and realities. Oncol Nurs Forum 1995 Jan-Feb;22(1):57-67.
  28. Malkinson, FD. Radiobiology of the skin. In: Freedberg IM, Eisen AZ, Wolff K, Austen KF, Goldsmith LA, Katz SI, Fitzpatrick TB, editors. Fitzpatrick's dermatology in general medicine. 5th edn. New York: McGraw-Hill; 1999. pp. 1514-1523.
  29. Goldschmidt H, Breneman JC, Bareneman DL. Ionizing radiation therapy in dermatology. J Am Acad Dermatol 1994 Feb;30(2 Pt 1):157-182.
  30. Narkiewicz K, van de Borne P, Montano N, Hering D, Kara T, Somers VK. Sympathetic neural outflow and chemoreflex sensitivity are related to spontaneous breathing rate in normal men. Hypertension 2006;47(1):51-55.
  31. Agte VV, Chiplonkar SA. Sudarshan kriya yoga for improving antioxidant status and reducing anxiety in adults. Altern Complement Ther 2008;14(2):96-100.
  32. Jacobs GD. Clinical applications of the relaxation response and mind-body interventions. J Altern Complement Med 2001;7(Suppl 1):S93-S101.
  33. Singh N, Telles S. Heart rate variability and state anxiety in hypertensives and diabetes after one week of yoga. J Indian Psychol 2009;27(1-2):13-20.
  34. Williams B, Poulter NR, Brown MJ, Davis M, McInnes GT, Potter JF, Sever PS, McG Thom S; British Hypertension Society. Guidelines for management of hypertension: report of the fourth working party of the British Hypertension Society, 2004—BHS IV. J Hum Hypertens 2004 Mar;18(3):139-185.
  35. Rabi DM, Daskalopoulou SS, Padwal RS, Khan NA, Grover SA, Hackam DG, Myers MG, McKay DW, Quinn RR, Hemmelgarn BR, et al. The 2011 Canadian Hypertension Education Program recommendations for the management of hypertension: blood pressure measurement, diagnosis, assessment of risk, and therapy. Can J Cardiol 2011 Jul-Aug;27(4):415-433.e1-2.
  36. Wahlgren NG, MacMahon DG, De Keyser JF, Indredavik B, Ryman T. Intravenous Nimodipine West European Stroke Trial (INWEST) of nimodipine in the treatment of acute ischaemic stroke. Cerebrovasc Dis 1994 May;4(3):204-10.
  37. Kaste M, Fogelholm R, Erilä T, Palomäki H, Murros K, Rissanen A, Sarna S. A randomized, double-blind, placebo-controlled trial of nimodipine in acute ischemic hemispheric stroke. Stroke 1994 Jul;25(7):1348-1353.
  38. Schrader J, Lüders S, Kulschewski A, Berger J, Zidek W, Treib J, Einhaupl K, Diener HC, Dominiak P; Acute Candesartan Cilexetil Therapy in Stroke Survivors Study Group. The ACCESS study: evaluation of Acute Candesartan Cilexetil Therapy in Stroke Survivors. Stroke 2003 Jul;34(7):1699-1703.
  39. Sandset EC, Bath PM, Boysen G, Jatuzis D, Kõrv J, Lüders S, Murray GD, Richter PS, Roine RO, Terént A, et al. The angiotensin-receptor blocker candesartan for treatment of acute stroke (SCAST): a randomised, placebo-controlled, double-blind trial. Lancet 2011 Feb;377(9767):741-750.
  40. Potter JF, Robinson TG, Ford GA, Mistri A, James M, Chernova J, Jagger C. Controlling hypertension and hypotension immediately post-stroke (CHHIPS): a randomised, placebo-controlled, double-blind pilot trial. Lancet Neurol 2009 Jan;8(1):48-56.
  41. Robinson TG, Potter JF, Ford GA, Bulpitt CJ, Chernova J, Jagger C, James MA, Knight J, Markus HS, Mistri AK, et al. Effects of antihypertensive treatment after acute stroke in the Continue or Stop Post-Stroke Antihypertensives Collaborative Study (COSSACS): a prospective, randomised, open, blinded-endpoint trial. Lancet Neurol 2010 Aug;9(8):767-775.
  42. Jauch EC, Saver JL, Adams HP, Bruno A, Demaerschalk BM, Khatri P, McMullan PW, Qureshi AI, Rosenfield K, Scott PA, et al. Guidelines for the early management of patients with acute ischemic stroke. Stroke 2013 Mar;44(3):870-947.
  43. Ahmed N, Wahlgren N, Brainin M, Castillo J, Ford GA, Kaste M, Lees KR, Toni D; SITS Investigators. Relationship of blood pressure, antihypertensive therapy, and outcome in ischemic stroke treated with intravenous thrombolysis. Stroke 2009 Jul;40(7):2442-2449.
  44. Karachalios GN, Charalabopoulos A, Papalimneou V, Kiortsis D, Dimicco P, Kostoula OK, Charalabopoulos K. Withdrawal syndrome following cessation of antihypertensive drug therapy. Int J Clin Pract 2005 May;59(5):562-570.
  45. PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet 2001 Sep;358(9287):1033-1041.
  46. Schrader J, Lüders S, Kulschewski A, Hammersen F, Plate K, Berger J, Zidek W, Dominiak P, Diener HC; MOSES Study Group. Morbidity and mortality after stroke, eprosartan compared with nitrendipine for secondary prevention. Stroke 2005 Jun;36(6):1218-1226.
  47. Yusuf S, Diener HC, Sacco RL, Cotton D, Ôunpuu S, Lawton WA, Palesch Y, Martin RH, Albers GW, Bath P, et al. Telmisartan to prevent recurrent stroke and cardiovascular events. N Engl J Med 2008 Sep;359(12):1225-1237.
  48. Kernan WN, Ovbiagele B, Black HR, Bravata DM, Chimowitz MI, Ezekowitz MD, Fang MC, Fisher M, Furie KL, Heck DV, et al. Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack. Stroke 2014 Jan:45(7):2160-2236.
  49. Robb AO, Mills NL, Din JN, Smith IB, Paterson F, Newby DE, Denison FC. Influence of the menstrual cycle, pregnancy, and preeclampsia on arterial stiffness. Hypertension 2009 Jun;53(6):952-958.
  50. Avni B, Frenkel G, Shahar L, Golik A, Sherman D, Dishy V. Aortic stiffness in normal and hypertensive pregnancy. Blood Press 2010 Feb;19(1):11-15.
  51. Khalil A, Akolekar R, Syngelaki A, Elkhouli M, Nicolaides KH. Maternal hemodynamics at 11–13 weeks’ gestation and risk of pre-eclampsia. Ultrasound Obstet Gynecol 2012 Jul;40(1):28-34.
  52. Medical Research Council trial of treatment of hypertension in older adults: principal results. MRC Working Party. BMJ 1992 Feb;304(6824):405-412.
  53. Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, Faire U, Fyhrquist F, Ibsen H, Kristiansson K, Lederballe-Pedersen O, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002 Mar;359(9311):995-1003.
  54. Dahlof B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trials-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005 Sep;366(9489):895-906.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.